Business Context and Reporting Period
This Form 8-K reports the consummation of a business combination between Semper Paratus Acquisition Corporation and Tevogen Bio Inc. on February 14, 2024. Following the merger, Semper Paratus domesticated from the Cayman Islands to Delaware and changed its name to Tevogen Bio Holdings Inc. (the "Company"). The Company is a clinical-stage biopharmaceutical company focused on developing cellular therapy product candidates, specifically utilizing its ExacTcell platform. The Company has no products approved for commercial sale and has a history of significant losses.
Key Financial Metrics and Capital Structure
Debt and Liquidity: The Company assumed seven convertible promissory notes from Tevogen Bio with an aggregate principal amount of approximately $24.0 million. These notes were automatically converted immediately following the closing into 10,337,419 shares of Common Stock. The filing does not provide specific cash balance or liquidity figures for the post-combination entity, referring instead to the Definitive Proxy Statement for audited and unaudited financial statements.
Capitalization: As of February 14, 2024, 163,754,418 shares of Common Stock were issued and outstanding. The Company's securities trade on The Nasdaq Stock Market LLC under the symbols "TVGN" (Common Stock) and "TVGNW" (Warrants).
Revenue and Profitability: The filing states the Company has never generated revenue from product sales and expects to continue to incur significant losses for the foreseeable future. No specific revenue or net income figures are provided in this report.
Material Changes and Corporate Actions
- Change of Control: A change of control occurred as a result of the business combination. Dr. Ryan Saadi holds 72.3% of the outstanding shares immediately following the transaction.
- Stock Conversion: Pre-existing Tevogen Bio shares were converted into Company Common Stock based on an exchange ratio derived from a $1.2 billion equity value and a $10.00 per share reference price.
- Earnout Shares: The Company may issue up to 20,000,000 shares to former Tevogen Bio stockholders and up to 4,500,000 shares to the Sponsor over 36 months upon the occurrence of certain triggering events.
- Executive Compensation: Dr. Saadi received a "Special RSU Award" of 19,429,620 RSUs, which immediately vested into restricted stock subject to a four-year vesting schedule beginning in 2031.
Guidance, Risks, and Management Commentary
Outlook and Financing Needs: Management states the Company will require substantial additional financing to pursue its business objectives, which may not be available on acceptable terms. The Company intends to retain all earnings for business operations and does not intend to pay cash dividends.
Key Risks:
- Limited operating history and no approved products.
- Dependence on the first product candidate, TVGN 489.
- Uncertainty regarding regulatory approval and clinical trial outcomes.
- Manufacturing risks associated with cell therapies.
- Management team has no prior experience managing a public company.
Lock-Up Agreements: Significant holders, including the Sponsor and Dr. Saadi, are subject to a lock-up agreement preventing transfers for six months or until the stock price exceeds $12.00 per share for 20 trading days within a 30-day period (commencing 150 days post-closing).
Investor Verification Checklist
- Verify the specific cash position and burn rate in the Definitive Proxy Statement, as this 8-K does not list current cash balances.
- Review the terms of the $24.0 million convertible notes and confirm the full conversion to equity.
- Assess the concentration risk given Dr. Saadi's 72.3% ownership stake.
- Examine the "Earnout Shares" triggering events to understand potential future dilution.
- Confirm the status of the first product candidate, TVGN 489, and upcoming clinical trial milestones.
- Review the Definitive Proxy Statement for the full text of the Merger Agreement and Risk Factors.